Clinical Assessment of Two Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lenses

NCT ID: NCT04980456

Last Updated: 2023-01-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

257 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-05

Study Completion Date

2021-11-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the clinical performance of TOTAL30 contact lenses with Biofinity contact lenses over 30 days of daily wear.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will wear two products and be expected to attend 4 office visits. The individual duration of participation will be approximately 65 days, which includes approximately 30 days of exposure to the test product and approximately 30 days of exposure to the comparator product.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TOTAL30, then Biofinity

Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses as randomized. Each study product will be worn bilaterally (in both eyes) for approximately 30 days for at least 10 hours per day during waking hours only. CLEAR CARE will be used for daily cleaning and disinfection.

Group Type OTHER

Lehfilcon A contact lenses

Intervention Type DEVICE

Investigational silicone hydrogel contact lenses

Comfilcon A contact lenses

Intervention Type DEVICE

Commercially available silicone hydrogel contact lenses

CLEAR CARE

Intervention Type DEVICE

Hydrogen peroxide-based cleaning and disinfecting solution

Biofinity, then TOTAL30

Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each study product will be worn bilaterally (in both eyes) for at least 10 hours per day during waking hours only. CLEAR CARE will be used for daily cleaning and disinfection.

Group Type OTHER

Lehfilcon A contact lenses

Intervention Type DEVICE

Investigational silicone hydrogel contact lenses

Comfilcon A contact lenses

Intervention Type DEVICE

Commercially available silicone hydrogel contact lenses

CLEAR CARE

Intervention Type DEVICE

Hydrogen peroxide-based cleaning and disinfecting solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lehfilcon A contact lenses

Investigational silicone hydrogel contact lenses

Intervention Type DEVICE

Comfilcon A contact lenses

Commercially available silicone hydrogel contact lenses

Intervention Type DEVICE

CLEAR CARE

Hydrogen peroxide-based cleaning and disinfecting solution

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TOTAL30 CooperVision® Biofinity® Biofinity

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to understand and sign an approved Informed Consent form;
* Willing and able to attend all scheduled study visits as required by the protocol;
* Currently wearing any commercial spherical weekly/monthly soft contact lenses in both eyes for at least 3 months, minimum 5 days per week, 10 hours per day;
* Manifest cylinder less than or equal to 0.75 diopter (D) in each eye;
* Willing to stop wearing habitual contact lenses for the duration of study participation.

Exclusion Criteria

* Any eye condition that contraindicates contact lens wear, as determined by the Investigator;
* Any use of systemic or ocular medicine that contraindicates contact lens wear, as determined by the Investigator;
* Ocular or intraocular surgery (excluding placement of punctal plugs) within the previous 12 months or planned during the study;
* Any use of topical ocular medications and artificial tear or rewetting drops that would require instillation during contact lens wear;
* Current or prior Biofinity contact lens wear in the past 3 months prior to consent.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trial Lead, Vision Care

Role: STUDY_DIRECTOR

Alcon Research, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alcon Investigator 8135

Los Angeles, California, United States

Site Status

Alcon Investigator 8062

Oakland, California, United States

Site Status

Alcon Investigator 8106

San Francisco, California, United States

Site Status

Alcon Investigator 6356

Longwood, Florida, United States

Site Status

Alcon Investigator 6565

Maitland, Florida, United States

Site Status

Alcon Investigator 6654

West Palm Beach, Florida, United States

Site Status

Alcon Investigator 6567

Pittsburg, Kansas, United States

Site Status

Alcon Investigator 5582

Louisville, Kentucky, United States

Site Status

Alcon Investigator 8097

Sterling Heights, Michigan, United States

Site Status

Alcon Investigator 7980

Willmar, Minnesota, United States

Site Status

Alcon Investigator 8130

New York, New York, United States

Site Status

Alcon Investigator 6401

Warwick, Rhode Island, United States

Site Status

Alcon Investigator 6353

Memphis, Tennessee, United States

Site Status

Alcon Investigator 8175

Austin, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CLY935-C019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.